Follow The Filings

MED Medifast

Medifast earnings company data as of 4:45 AM ET 10/16

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 2 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by MED's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MED insider trades
  • $1.7M bought by 3 insiders
  • None no sales outside a trading plan
  • $226K sold by 1 insider under 10b5-1 plans
  1. Daniel R Chard Director
    Planned sale
    $226K 19,089 shares at $11.85 13% of stake
    Traded Sep 28–29 Filed Sep 30
  2. Parsa Kiai Director
    Buy
    $529K 43,150 shares at $12.26 New stake
    Traded Aug 26 Filed Aug 28
  3. Parsa Kiai Director
    Buy
    $52K 4,329 shares at $12.00 +29% to stake
    Traded Aug 24 Filed Aug 26
  4. Parsa Kiai Director
    Buy
    $843K 72,487 shares at $11.63 New stake
    Traded Aug 19–20 Filed Aug 21
  5. Scott Schlackman Director
    Buy
    $63K 5,000 shares at $12.59 +20% to stake
    Traded May 8–11 Filed May 12
  6. Daniel R Chard CEO
    Buy
    $179K 17,678 shares at $10.11 New stake
    Traded Mar 20 Filed Mar 27

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants and 9 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13D/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
8-K 7.01,9.01
8-K 5.02,9.01
8-K 5.02,5.07,7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEFA14A
DEF 14A
DEFA14A
SCHEDULE 13G/A —
SCHEDULE 13D —
8-K 1.01,5.02,7.01,9.01
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.